{"id":566573,"date":"2026-09-09T22:00:00","date_gmt":"2026-09-09T20:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/approches-therapeutiques-ciblant-les-parp-moleculaires-et-immunologiques\/"},"modified":"2026-09-21T10:59:33","modified_gmt":"2026-09-21T08:59:33","slug":"approches-therapeutiques-ciblant-les-parp-moleculaires-et-immunologiques","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/approches-therapeutiques-ciblant-les-parp-moleculaires-et-immunologiques\/","title":{"rendered":"Approches th\u00e9rapeutiques ciblant les PARP, mol\u00e9culaires et immunologiques"},"content":{"rendered":"\n

Lors du congr\u00e8s de l\u2019ASCO 2026, diverses approches th\u00e9rapeutiques du cancer de l\u2019ovaire s\u00e9reux de haut grade (HGSOC) ont \u00e9t\u00e9 pr\u00e9sent\u00e9es. Cela comprenait des donn\u00e9es r\u00e9centes sur la caract\u00e9risation g\u00e9nomique de la HRD dans le cadre du traitement d\u2019entretien par PARP, ainsi que des r\u00e9sultats concernant le traitement n\u00e9oadjuvant par le conjugu\u00e9 anticorps-m\u00e9dicament ciblant le FR\u03b1, associ\u00e9 au carboplatine. Des approches immunologiques telles que l\u2019inhibition des points de contr\u00f4le, les strat\u00e9gies vaccinales et les th\u00e9rapies cellulaires adoptives ont \u00e9galement \u00e9t\u00e9 abord\u00e9es.<\/strong><\/p>\n\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

Lors du congr\u00e8s de l\u2019ASCO 2026, diverses approches th\u00e9rapeutiques du cancer de l\u2019ovaire s\u00e9reux de haut grade (HGSOC) ont \u00e9t\u00e9 pr\u00e9sent\u00e9es. Cela comprenait des donn\u00e9es r\u00e9centes sur la caract\u00e9risation g\u00e9nomique……... <\/p>\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":566574,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"HGSOC","footnotes":"","_members_access_role":[],"_members_access_error":""},"category":[11549,11527,11422,11389,11535],"tags":[102045,57902,102048,101584,102061,102050,102046,51235,19457,14687,102059,102057,24341,102055,102053],"powerkit_post_featured":[],"class_list":["post-566573","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-fr","category-etudes","category-gynecologie","category-oncologie","category-rapports-de-congres","tag-brca1-2","tag-carboplatine","tag-carcinome-ovarien-sereux-de-haut-grade","tag-congres-annuel-de-lasco-2026","tag-conjugues-anticorps-medicament-adc","tag-deficit-de-recombinaison-homologue-hrd","tag-hgsoc","tag-immunotherapie-fr-2","tag-inhibiteurs-de-la-parp","tag-inhibiteurs-de-points-de-controle","tag-mirvetuximab-soravtansine","tag-recepteur-alpha-du-folate-fr","tag-traitement-neoadjuvant","tag-traitement-dentretien-parp","tag-wgs-hrd","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-10-16 00:42:05","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":566577,"slug":"approcci-terapeutici-basati-sulle-parp-molecolari-e-immunologici","post_title":"Approcci terapeutici basati sulle PARP, molecolari e immunologici","href":"https:\/\/medizinonline.com\/it\/approcci-terapeutici-basati-sulle-parp-molecolari-e-immunologici\/"},"pt_PT":{"locale":"pt_PT","id":566585,"slug":"abordagens-terapeuticas-baseadas-na-parp-moleculares-e-imunologicas","post_title":"Abordagens terap\u00eauticas baseadas na PARP, moleculares e imunol\u00f3gicas","href":"https:\/\/medizinonline.com\/pt-pt\/abordagens-terapeuticas-baseadas-na-parp-moleculares-e-imunologicas\/"},"es_ES":{"locale":"es_ES","id":566602,"slug":"enfoques-terapeuticos-basados-en-parp-moleculares-e-inmunologicos","post_title":"Enfoques terap\u00e9uticos basados en PARP, moleculares e inmunol\u00f3gicos","href":"https:\/\/medizinonline.com\/es\/enfoques-terapeuticos-basados-en-parp-moleculares-e-inmunologicos\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/566573","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=566573"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/566573\/revisions"}],"predecessor-version":[{"id":566959,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/566573\/revisions\/566959"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/566574"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=566573"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=566573"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=566573"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=566573"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}